IM Cannabis Corp. (NASDAQ:IMCC – Get Free Report) saw a large growth in short interest in September. As of September 30th, there was short interest totaling 74,661 shares, a growth of 64.4% from the September 15th total of 45,409 shares. Currently, 38.3% of the shares of the stock are short sold. Based on an average daily volume of 14,912,101 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analyst Weigh In
IMCC has been the subject of a number of analyst reports. Wall Street Zen lowered IM Cannabis to a “strong sell” rating in a research report on Saturday, October 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IM Cannabis in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Check Out Our Latest Research Report on IMCC
IM Cannabis Stock Performance
Shares of IMCC opened at $1.33 on Friday. The stock has a market capitalization of $1.32 million, a PE ratio of -0.02 and a beta of 2.21. The stock has a 50-day simple moving average of $2.65 and a 200-day simple moving average of $5.49. IM Cannabis has a 1 year low of $1.20 and a 1 year high of $77.10.
IM Cannabis (NASDAQ:IMCC – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $5.34 million during the quarter.
IM Cannabis Company Profile
IM Cannabis Corp. is a medical cannabis company focused on the cultivation, importation, distribution and sale of cannabis products. The company markets products under the IMC brand and serves patients through regulated medical cannabis channels.
IM Cannabis operates primarily in Israel and Germany. In Israel, the company’s activities include supplying medical cannabis products through pharmacies and other authorized distribution channels. In Germany, it participates in the medical cannabis market through the importation and distribution of pharmaceutical-grade products.
The company was established in 2018 and has developed its business through subsidiaries and strategic partnerships in its target markets.
See Also
- Five stocks we like better than IM Cannabis
- Securitize’s Blockchain Ambitions Face a Reality Check
- 3 Stocks to Watch as Wall Street Wealth Fuels Consumer Spending
- Expecting a Market Correction? This Mega-Cap ETF Deserves a Spot on Your Watchlist
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
